Paige is a NY-based healthtech startup that uses artificial intelligence to help doctors diagnose cancer. The company’s AI software has been trained by looking through large amounts of clinical imaging data in order to spot cancerous cells. Usually, doctors have to rely on their own eyes to scan medical imaging for cancer cells, but with Paige it becomes easier to make that diagnosis.
Paige’s technology attracted the attention of investors in late 2019 when it raised $45 million in Series B funding. Now, just a few months later, more investors are looking to back the startup.
On Thusday, Paige announced that it raised an additional $5 million in funding, bringing its Series B total to $50 million. Goldman Sachs contributed this new investment, and its managing director David Castelblanco will be added to the company’s board of directors.
“We’re thrilled to be working with David Castelblanco and the team at Goldman Sachs as we build our platform and further develop our computational pathology infrastructure,” Paige CEO Leo Grady said in a statement. “With our new funding and leadership additions, we’ll focus on building network effects based on our clinical-grade digital pathology and AI platform.”
Paige plans to use this new investment to continue developing its product and acquire more customers internationally. The company is currently hiring for several roles in business development, product and engineering.
